Zhu Guangwei, Ye Jianxin, Huang Yongjian, Zheng Wei, Hua Jin, Yang Shugang, Zhuang Jinfu, Wang Jinzhou
Department of Gastrointestinal Surgery Section II, The First Hospital Affiliated to Fujian Medical University, Fuzhou, Fujian, P.R. China.
Int J Oncol. 2016 Jun;48(6):2387-98. doi: 10.3892/ijo.2016.3455. Epub 2016 Mar 24.
The receptor-interacting protein-1 (RIP-1) is an important molecular in inflammation signaling pathways, but the role of RIP-1 in gastric cancer is largely unknown. In this study, we tested the expression of RIP-1 in gastric cancer samples and analyzed the effects of expression of RIP-1 on the prognosis in gastric cancer patients. We analyzed the role of the RIP-1 in gastric cancer cells and addressed the functional role of RIP-1 using a xenograft mouse model. A lentivirus-based effective RIP-1 siRNA vector was infected into HGC and AGS cells. The effect of RIP-1 siRNA on HGC and AGS cells were investigated by cell proliferation assay and invasion assay. Furthermore, we examined the role of RIP-1-siRNA on HGC cells in the mice with subcutaneous xenograft tumor, and preliminarily analyzed the underlying mechanisms. The results indicated that the expression of RIP-1 in the gastric cancer tissues was significantly higher than the expression in the normal gastric tissues. Additionally, RIP-1 immunoreactivity was positive at the site of invasion, but little or no immunoreactivity was detected at the gastric cancer parts of interstitial substance. Gastric cancer patients with high expression of RIP-1 had a poor survival rate. RIP-1 expression in the gastric cancer cell lines were general. HGC-R-1-RNAi-LV inhibited HGC and AGS cell proliferation and invasion ability in vitro. RIP-NF-κB/AP-1-VEGF-C signaling pathways have a crucial role in the regulate the biological functions of HGC cells. HGC-R-1-RNAi-LV suppressed tumor growth in the HGC cell subcutaneous xenograft model. In conclusion, our data indicate that RIP-1 promote the growth and invasion of gastric cancer in vitro and in vivo, additionally providing evidence that targeting RIP-1 may be useful in the treatment of gastric cancer.
受体相互作用蛋白1(RIP-1)是炎症信号通路中的一种重要分子,但RIP-1在胃癌中的作用尚不清楚。在本研究中,我们检测了RIP-1在胃癌样本中的表达,并分析了RIP-1表达对胃癌患者预后的影响。我们分析了RIP-1在胃癌细胞中的作用,并使用异种移植小鼠模型探讨了RIP-1的功能作用。将基于慢病毒的有效RIP-1 siRNA载体感染HGC和AGS细胞。通过细胞增殖试验和侵袭试验研究RIP-1 siRNA对HGC和AGS细胞的影响。此外,我们研究了RIP-1-siRNA对皮下异种移植瘤小鼠HGC细胞的作用,并初步分析了其潜在机制。结果表明,RIP-1在胃癌组织中的表达明显高于正常胃组织。此外,RIP-1免疫反应性在侵袭部位呈阳性,但在间质物质的胃癌部分几乎未检测到或未检测到免疫反应性。RIP-1高表达的胃癌患者生存率较低。RIP-1在胃癌细胞系中的表达普遍。HGC-R-1-RNAi-LV在体外抑制HGC和AGS细胞的增殖和侵袭能力。RIP-NF-κB/AP-1-VEGF-C信号通路在调节HGC细胞的生物学功能中起关键作用。HGC-R-1-RNAi-LV在HGC细胞皮下异种移植模型中抑制肿瘤生长。总之,我们的数据表明,RIP-1在体外和体内促进胃癌的生长和侵袭,此外还提供了靶向RIP-1可能对胃癌治疗有用的证据。